Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Jul 26, 2018 11:40am

146 Views

Post# 28371410

RE:RE:Should we sell ? Or buy ?

Another newer poster.

Hmm.

Sales are likely slowly improving. The big ramp won't happen until the Fall at the earliest.

Meanwhile, the drug just got some free advertising by being included in the new treatment guidelines (first in 2 years). That's worth more than many drug rep visits :)

Summer time drift....

sdakota wrote: Here is some reality and numbers. Low price, low volume, no buyers. Please spare me the excuse that only you folks on this board are in the know and there are no buyers becuase of ignorance about TH. Price is dropping because sales are probably poor.

Bullboard Posts

Soma Gold poised to extend profitable track record